Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Nov 4, 2026.

SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis

Jincheng Xu, Xiaoyue Xu, Lina Jiang and 3 more

Respiratory Research · 2020 · CC BY

doi:10.1186/s12931-020-01445-6

Abstract

Background. Severe acute respiratory syndrome (SARS)-CoV-2-induced coronavirus disease-2019 (COVID-19) is a pandemic disease that affects > 2.8 million people worldwide, with numbers increasing dramatically daily. However, there is no specific treatment for COVID-19 and much remains unknown about this disease. Angiotensin-converting enzyme (ACE)2 is a cellular receptor of SARS-CoV-2. It is cleaved by type II transmembrane serine protease (TMPRSS)2 and disintegrin and metallopeptidase domain (ADAM)17 to assist viral entry into host cells. Clinically, SARS-CoV-2 infection may result in acute lung injury and lung fibrosis, but the underlying mechanisms of COVID-19 induced lung fibrosis are not fully understood.

Methods. The networks of ACE2 and its interacting molecules were identified using bioinformatic methods. Their gene and protein expressions were measured in human epithelial cells after 24 h SARS-CoV-2 infection, or in existing datasets of lung fibrosis patients.

Results. We confirmed the binding of SARS-CoV-2 and ACE2 by bioinformatic analysis. TMPRSS2, ADAM17, tissue inhibitor of metalloproteinase (TIMP)3, angiotensinogen (AGT), transformation growth factor beta (TGFB1), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF) A and fibronectin (FN) were interacted with ACE2, and the mRNA and protein of these molecules were expressed in lung epithelial cells. SARS-CoV-2 infection increased ACE2, TGFB1, CTGF and FN1 mRNA that were drivers of lung fibrosis. These changes were also found in lung tissues from lung fibrosis patients.

Conclusions. Therefore, SARS-CoV-2 binds with ACE2 and activates fibrosis-related genes and processes to induce lung fibrosis.

References 57

  1. 1.

    WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2020.

    Not in our library

  2. 2.

    WHO. Epidemic and pandemic-prone diseases, MERS situation update, January 2020. 2020.

    Not in our library

  3. 3.

    WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 125. 2020.

    Not in our library

  4. 4.

    Xie L, Liu Y, Xiao Y, Tian Q, Fan B, Zhao H, Chen W. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 2005;127:2119-2124.

    Not in our library10.1378/chest.127.6.2119

  5. 5.

    Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401-409.

    Not in our library10.1136/thx.2004.030205

  6. 6.

    Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antivir Res. 2017;143:142-150.

    Not in our library10.1016/j.antiviral.2017.03.022

  7. 7.
    Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study · 2020
    Corrected
  8. 8.

    Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020;92:612-617.

    Not in our library10.1002/jmv.25735

  9. 9.

    Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425-434.

    Not in our library10.1016/s1473-3099(20)30086-4

  10. 10.

    Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30:3306–9.

    Not in our library10.1007/s00330-020-06731-x

  11. 11.

    Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30:4381–9.

    Not in our library10.1007/s00330-020-06801-0

  12. 12.

    Conti P, Gallenga C, Tetè G, Caraffa A, Ronconi G, Younes A, Toniato E, Ross R, Kritas S. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020;34. 10.23812/Editorial-Conti-2.

    Not in our library10.23812/editorial-conti-2

  13. 13.

    Zhang W. Imaging changes of severe COVID-19 pneumonia in advanced stage. Intensive Care Med. 2020;46:841-843.

    Not in our library10.1007/s00134-020-05990-y

  14. 14.

    Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med. 2020;382:692-694.

    Not in our library10.1056/nejmp2000929

  15. 15.

    Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.

    Not in our library10.1016/j.cell.2020.02.052

  16. 16.

    Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008;105:7809-7814.

    Not in our library10.1073/pnas.0711241105

  17. 17.

    Lasso G, Mayer SV, Winkelmann ER, Chu T, Elliot O, Patino-Galindo JA, Park K, Rabadan R, Honig B, Shapira SD. A structure-informed atlas of human-virus interactions. Cell. 2019;178:1526–41.

    Not in our library10.1016/j.cell.2019.08.005

  18. 18.
    GeneMANIA update 2018 · 2018
    No notice
  19. 19.

    Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88:1293-1307.

    Not in our library10.1128/jvi.02202-13

  20. 20.
    STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets · 2018
    No notice
  21. 21.

    Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580-585.

    Not in our library10.1038/ng.2653

  22. 22.

    Consortium GT: Human genomics. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648-660.

    Not in our library10.1126/science.1262110

  23. 23.

    Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. roteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.

    Not in our library10.1126/science.1260419

  24. 24.

    Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.

    Not in our library10.1126/science.aan2507

  25. 25.
    SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells · 2020
    No notice
  26. 26.

    Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen CI, Ren Z, et al. Single-cell Transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med. 2019;199:1517-1536.

    Not in our library10.1164/rccm.201712-2410oc

  27. 27.

    Blanco-Melo D, Nilsson-Payant B, Liu W-C, Uhl S, Hoagland D, Moeller R, Jordan T, Oishi K, Panis M, Sachs D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 2020;181:1036–45.

    Not in our library10.1016/j.cell.2020.04.026

  28. 28.

    Li J, Xu X, Jiang Y, Hansbro NG, Hansbro PM, Xu J, Liu G. Elastin is a key factor of tumor development in colorectal cancer. BMC Cancer. 2020;20:217.

    Not in our library10.1186/s12885-020-6686-x

  29. 29.

    Bhattacharya S, Srisuma S, Demeo DL, Shapiro SD, Bueno R, Silverman EK, Reilly JJ, Mariani TJ. Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol. 2009;40:359-367.

    Not in our library10.1165/rcmb.2008-0114oc

  30. 30.

    Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, Barr RG, Bleecker ER, et al. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. J Clin Invest. 2019;129:169-181.

    Not in our library10.1172/jci121087

  31. 31.

    Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, Choi AM. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203:2895-2906.

    Not in our library10.1084/jem.20061536

  32. 32.
    Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis · 2005
    No notice
  33. 33.

    Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol. 2008;172:583-591.

    Not in our library10.2353/ajpath.2008.070569

  34. 34.

    Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180:167-175.

    Not in our library10.1164/rccm.200810-1596oc

  35. 35.

    Yamashita CM, Dolgonos L, Zemans RL, Young SK, Robertson J, Briones N, Suzuki T, Campbell MN, Gauldie J, Radisky DC, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179:1733-1745.

    Not in our library10.1016/j.ajpath.2011.06.041

  36. 36.
    MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis · 2008
    No notice
  37. 37.

    Kaiko GE, Chen F, Lai CW, Chiang IL, Perrigoue J, Stojmirovic A, Li K, Muegge BD, Jain U, VanDussen KL, et al. PAI-1 augments mucosal damage in colitis. Sci Transl Med. 2019;11:eaat0852.

    Not in our library10.1126/scitranslmed.aat0852

  38. 38.

    Xu X, Ling M, Inglis SC, Hickman L, Parker D. Eating and healthy ageing: a longitudinal study on the association between food consumption, memory loss and its comorbidities. Int J Public Health. 2020. 10.1007/s00038-020-01337-y.

    Not in our library10.1007/s00038-020-01337-y

  39. 39.

    Liu G, Baird AW, Parsons MJ, Fan K, Skerrett-Byrne DA, Nair PM, Makanyengo S, Chen J, Neal R, Goggins BJ, et al. Platelet activating factor receptor acts to limit colitis-induced liver inflammation. FASEB J. 2020;34:7718–32.

    Not in our library10.1096/fj.201901779r

  40. 40.

    Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127–20.

    Not in our library10.1128/jvi.00127-20

All 57 references

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.